New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
Jayne Hornung
Advertisement
Chief clinical officer, MMIT (Managed Markets Insight & Technology).
Articles by Jayne Hornung
Advertisement
Latest Updated Articles
When Will Payers Improve Coverage of Prescription Digital Therapeutics?Published: July 22nd 2022 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
